AOD 9604 peptide vs retatrutide compared: how the fat-loss fragment and the triple-agonist shot differ in mechanism, dosing, trial results, and legal status.
AOD 9604 is a modified fragment of human growth hormone that researchers have studied for fat loss, while retatrutide is an investigational triple-agonist drug that switches on three hormone receptors at once. Neither one is FDA-approved for weight loss in the United States. The two get compared because both come up in fat-loss discussions, but they differ sharply in how they work, how strong the evidence is, how they are dosed, and whether you can legally obtain them.
What Is AOD 9604?
AOD 9604 is a 16-amino-acid peptide modeled on the tail end of human growth hormone, also called HGH fragment 176-191. It was designed to keep growth hormone's fat-burning activity while avoiding its effects on blood sugar and tissue growth.
Developers ran small human trials in the 2000s. Those studies reported only modest fat loss compared with placebo, and results were not consistent across doses or study groups.
Today, AOD 9604 is sold online as a research chemical or research peptide. Products in that category are not reviewed by the FDA for purity, sterility, or actual contents, so what is inside the vial is frequently unknown.
What Is Retatrutide?
Retatrutide is an investigational drug from Eli Lilly that activates three receptors at once: GLP-1, GIP, and glucagon. That triple action is why it is often described as a triple agonist.
In a phase 2 trial published in 2023, adults with obesity who received the highest dose lost about 24% of their body weight over 48 weeks. No approved weight-loss medication had produced that level of loss at the time.
Retatrutide is now being tested in phase 3 trials for obesity and type 2 diabetes. It is not commercially available, and it cannot be legally prescribed or purchased outside of a clinical trial.
Head-to-Head Comparison
When people look up aod 9604 peptide vs retatrutide, the comparison usually comes down to four things: mechanism, evidence, dosing, and legal status.
| Category | AOD 9604 | Retatrutide |
|---|---|---|
| Type | Modified HGH fragment (peptide) | Synthetic triple agonist (single molecule) |
| Targets | Fat-cell lipolysis | GLP-1, GIP, and glucagon receptors |
| Route | Subcutaneous injection | Subcutaneous injection |
| Typical research dose | 300 mcg once or twice daily | Once weekly, titrated upward (e.g., 1 mg to 12 mg) |
| Weight loss in trials | Modest and inconsistent versus placebo | Up to roughly 24% of body weight at 48 weeks |
| FDA status | Not approved for any human use | Investigational; not approved |
| Legal availability | Sold as a research chemical only | Clinical trials only |
| Common side effects | Injection-site irritation | Nausea, vomiting, diarrhea, constipation |
How Their Mechanisms Differ
AOD 9604 acts locally on fat cells. It mimics one segment of growth hormone to trigger lipolysis, the breakdown of stored fat, without raising IGF-1 or driving growth.
Retatrutide acts through the brain and the endocrine system. GLP-1 and GIP activity suppresses appetite and slows stomach emptying, while glucagon receptor activation appears to raise energy expenditure.
One is a narrow metabolic fragment with a single apparent job. Retatrutide is a system-wide drug that changes appetite, digestion, insulin signaling, and calorie burn at the same time. That difference explains most of the gap in weight loss between them.
Dosing and Administration
- AOD 9604: subcutaneous injections, usually 300 mcg once or twice daily in research protocols. There is no FDA-reviewed dosing guidance for humans.
- Retatrutide: a once-weekly subcutaneous injection that is slowly titrated over months, following schedules such as 1 mg, 2 mg, 4 mg, 8 mg, and 12 mg in trial designs.
When people compare aod 9604 vs retatrutide, the once-weekly convenience of retatrutide often comes up. That schedule exists to manage gastrointestinal side effects, not because the drug is gentler on the body.
There is also no clinical data on using aod-9604 peptide with retatrutide in the same person. Combining an unapproved peptide with an investigational drug adds unknown risks without adding proven benefits.
Side Effects and Safety
Reported AOD 9604 side effects are mostly mild and limited to injection-site irritation, but human safety data remain thin. Long-term effects on hormones, pregnancy, and liver health have not been established.
Retatrutide's side effect profile looks like the GLP-1 class: nausea, vomiting, diarrhea, and constipation, especially during dose increases. Trials have also flagged rises in resting heart rate and gallbladder problems, and rapid weight loss can cost lean muscle mass.
Neither substance is a casual supplement. Anyone weighing either option should review their medications and health history with a licensed healthcare professional, because weight-loss drugs can interact with other treatments and are not appropriate for everyone.
Legal Status and Availability in the US
The FDA has not approved AOD 9604 for any human use. It is not a lawful prescription medication, and online sellers operate in a gray market where labels are not verified.
Retatrutide is an investigational new drug. It cannot legally be sold, prescribed, or shipped to consumers, and vials sold under that name are unverified.
Readers comparing aod-9604 peptide vs tesamorelin will find a different situation, since Tesamorelin is FDA-approved for HIV-related lipodystrophy. That approval does not make it a general weight-loss drug, and it does not apply to AOD 9604.
Other Peptides People Compare
Aod 9604 vs mots-c is a different match-up entirely. MOTS-c is a mitochondrial-derived peptide studied for metabolic health rather than direct fat breakdown, so the two are not interchangeable.
Likewise, aod-9604 vs cjc-1295 ipamorelin comes up in bodybuilding circles because those peptides aim to raise growth hormone indirectly instead of delivering an HGH fragment. Stacking is where most of the risk lives, since research-grade peptides are frequently mislabeled and there is no trial data behind these combinations.
Bottom Line
Retatrutide has the stronger evidence by a wide margin: about 24% body-weight loss at 48 weeks in a phase 2 trial, compared with only modest and inconsistent fat loss for AOD 9604 in older studies.
Retatrutide also carries more serious side effects and is not legally available outside clinical trials. AOD 9604 is available only as an unapproved research chemical with no verified quality control.
The practical answer is that neither is a legal, FDA-approved weight-loss option today. Any decision about these compounds should run through a qualified healthcare provider rather than an online vendor.
Frequently Asked Questions
Is AOD 9604 or retatrutide FDA-approved?
Neither one is FDA-approved. AOD 9604 has never been approved for any human use in the United States and is sold only as an unapproved research chemical. Retatrutide is an investigational drug still in phase 3 clinical trials, so it cannot legally be prescribed or sold to consumers.
Which causes more weight loss, AOD 9604 or retatrutide?
Retatrutide has produced far greater weight loss in trials. In a 2023 phase 2 study, participants on the highest dose lost roughly 24% of their body weight over 48 weeks. AOD 9604 trials from the 2000s showed only modest and inconsistent fat loss compared with placebo.
Can you stack AOD 9604 with retatrutide?
There is no clinical research on combining the two, and retatrutide is not legally available outside a clinical trial. Adding an unapproved peptide to an investigational drug increases the chance of unpredictable side effects without proven benefit. Talk with a healthcare professional before combining any weight-loss compounds.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.